Fabio
7.4 KiB
type, title, description, jurisdiction, legislature, session, identifier, citation, classification, subjects, status, primary_sponsors, version_count, action_count, vote_count, first_action, last_action, source, source_identifier, source_url, source_hash, vintage, source_snapshot, retrieved_at, confidence, tags
| type | title | description | jurisdiction | legislature | session | identifier | citation | classification | subjects | status | primary_sponsors | version_count | action_count | vote_count | first_action | last_action | source | source_identifier | source_url | source_hash | vintage | source_snapshot | retrieved_at | confidence | tags | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bill | Health insurance; required provisions regarding prior authorization for prescription drugs. | Health insurance; carrier contracts; required provisions regarding prior authorization for prescription drugs. Amends existing required provisions for health carrier contracts related to prior authorizations for prescription drugs. Current law requires that if prior authorization is approved for prescription drugs and such prescription drugs have been scheduled, provided, or delivered to the patient consistent with the authorization, health carriers may not revoke, limit, condition, modify, or restrict that authorization except in certain circumstances. The bill requires this limitation on carriers to apply for the duration of the authorization, which the bill requires to be a minimum of six months for initial authorizations and a minimum of 12 months for continued authorizations. The bill adds circumstances under which a prior authorization may be revoked, limited, conditioned, modified, or restricted by a carrier, including (i) a final action by the U.S. Food and Drug Administration, other regulatory agencies, or the manufacturer communicating a patient efficacy issue that would affect the authorization and (ii) when additional safety and efficacy monitoring is clinically appropriate or recommended by the U.S. Food and Drug Administration, other regulatory agencies, or the manufacturer. | us/states/va | Virginia General Assembly | 2026 | HB 736 | Virginia HB 736 (2026) |
|
enacted |
|
6 | 31 | 8 | 2026-01-13 | 2026-04-06 | openstates | ocd-bill/03e36206-4752-4a50-bbaf-f0a136be1bf2 | https://lis.virginia.gov/bill-details/20261/HB736 | 0ff539eb9e33ad09341b65848343ec3d8d4b354744e1c0cfc17932838a44f0af | 2026-07-01 | https://data.openstates.org/daily/2026-07-01/public.pgdump | 2026-07-06 | reported |
|
Virginia HB 736 (2026) — Health insurance; required provisions regarding prior authorization for prescription drugs.
Health insurance; carrier contracts; required provisions regarding prior authorization for prescription drugs. Amends existing required provisions for health carrier contracts related to prior authorizations for prescription drugs. Current law requires that if prior authorization is approved for prescription drugs and such prescription drugs have been scheduled, provided, or delivered to the patient consistent with the authorization, health carriers may not revoke, limit, condition, modify, or restrict that authorization except in certain circumstances. The bill requires this limitation on carriers to apply for the duration of the authorization, which the bill requires to be a minimum of six months for initial authorizations and a minimum of 12 months for continued authorizations. The bill adds circumstances under which a prior authorization may be revoked, limited, conditioned, modified, or restricted by a carrier, including (i) a final action by the U.S. Food and Drug Administration, other regulatory agencies, or the manufacturer communicating a patient efficacy issue that would affect the authorization and (ii) when additional safety and efficacy monitoring is clinically appropriate or recommended by the U.S. Food and Drug Administration, other regulatory agencies, or the manufacturer.
Version chain
The bill's text revisions, in order — the diff chain from filing to enrollment.
- Introduced (filed) — source
- Chaptered (committee substitute) — source
- Engrossed (committee substitute) — source
- Labor and Commerce Amendment (committee substitute) — source
- Subcommittee #1 Subcommittee Amendment (committee substitute) — source
- Enrolled (enrolled) — source
Votes
- Reported from Labor and Commerce with amendment(s) — 22–0 (pass) · lower
- Reported from Commerce and Labor — 13–0 (pass) · upper
- Subcommittee recommends reporting — 7–0 (pass) · lower
- H VOTE: — 96–0 (pass) · lower
- Subcommittee recommends reporting with amendment(s) — 9–0 (pass) · lower
- Reported from Appropriations — 22–0 (pass) · lower
- Passage R — 39–0 (pass) · upper
- Constitutional reading dispensed (on 2nd reading) — 39–0 (pass) · upper
Sponsors
- Michelle Lopes Maldonado — primary (person)
- Amy J. Laufer — cosponsor (person)
Timeline
The legislative action history — every referral, reading, and vote.
- 2026-01-13 Prefiled and ordered printed; Offered 01-14-2026 26105188D
filing, introduction - 2026-01-13 Referred to Committee on Labor and Commerce
referral-committee - 2026-01-20 Assigned HCL sub: Subcommittee #1
referral-committee - 2026-02-03 Subcommittee recommends reporting with amendment(s) and referring to Appropriations (9-Y 0-N)
- 2026-02-05 Reported from Labor and Commerce with amendment(s) and referred to Appropriations (22-Y 0-N)
committee-passage - 2026-02-05 Assigned HAPP sub: Compensation and Retirement
referral-committee - 2026-02-13 Subcommittee recommends reporting (7-Y 0-N)
- 2026-02-13 Reported from Appropriations (22-Y 0-N)
committee-passage - 2026-02-15 Read first time
reading-1 - 2026-02-16 Read second time
reading-2 - 2026-02-16 committee amendments agreed to
amendment-passage - 2026-02-16 Engrossed by House as amended
- 2026-02-17 Fiscal Impact Statement from Department of Planning and Budget (HB736)
- 2026-02-17 Read third time and passed House (97-Y 0-N 0-A)
passage, reading-3 - 2026-02-18 Constitutional reading dispensed (on 1st reading)
- 2026-02-18 Referred to Committee on Commerce and Labor
referral-committee - 2026-03-02 Reported from Commerce and Labor (13-Y 0-N)
committee-passage - 2026-03-04 Rules suspended
- 2026-03-04 Constitutional reading dispensed (on 2nd reading) (39-Y 0-N 0-A)
- 2026-03-04 Passed by for the day (Voice Vote)
- 2026-03-05 Read third time
reading-3 - 2026-03-05 Passed Senate (39-Y 0-N 0-A)
passage - 2026-03-12 Enrolled
enrolled - 2026-03-12 Bill text as passed House and Senate (HB736ER)
passage - 2026-03-12 Fiscal Impact Statement from Department of Planning and Budget (HB736)
- 2026-03-12 Signed by Speaker
passage - 2026-03-12 Signed by President
passage - 2026-03-14 Enrolled Bill communicated to Governor on March 14, 2026
enrolled, executive-receipt - 2026-03-14 Governor's Action Deadline 11:59 p.m., April 13, 2026
executive-receipt - 2026-04-06 Approved by Governor-Chapter 213 (effective 7/1/2026)
executive-signature - 2026-04-06 Acts of Assembly Chapter text (CHAP0213)
Source
OpenStates / OpenCivicData bulk snapshot 2026-07-01; origin ocd-bill/03e36206-4752-4a50-bbaf-f0a136be1bf2. Confidence: reported (aggregated from official Virginia legislature records).